Decentralized clinical trials (DCTs), which shift study visits, data collection, and drug delivery away from a central site and toward the patient's home, were marketed for a decade as the fix for slow, expensive, unrepresentative trial recruitment. The regulatory scaffolding has now caught up: the FDA issued final guidance on Conducting Clinical Trials With Decentralized Elements in September 2024, giving sponsors a clearer regulatory pathway. Source: FDA guidance, Conducting Clinical Trials With Decentralized Elements.
What has arrived alongside the regulatory clarity is something the DCT industry mostly did not commission itself: independent research measuring whether decentralization actually delivers the recruitment speed, diversity, and cost benefits it promised.
What does the FDA guidance actually permit?
The guidance, issued jointly by the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, the Center for Devices and Radiological Health, and the Oncology Center of Excellence, clarifies acceptable use of local health care providers, telehealth visits, mobile and local labs, and direct-to-participant investigational product shipment, while maintaining that data quality, participant safety oversight, and investigator responsibility standards remain unchanged from traditional trials. Source: Federal Register notice, September 2024, HHS Guidance Portal summary.
The critical regulatory point: decentralization is treated as a set of optional elements that can be layered onto a trial, not a separate category of trial with its own lower evidentiary bar. A fully decentralized, hybrid, or traditional site-based trial are all held to the same standard for data integrity and participant protection.
What does the independent evidence show about DCT performance?
A 2025 paper in npj Digital Medicine, "Understanding the gap between expectations and reality in decentralized clinical trials," is the most direct empirical reckoning published so far. The paper documents systematic gaps between the promised benefits of decentralization, faster enrollment, broader and more diverse participation, lower dropout, reduced cost, and what has actually been observed across implemented DCTs. Source: Understanding the gap between expectations and reality in DCTs, npj Digital Medicine 2025.
The recurring themes in this and related landscape analyses:
Recruitment speed gains are real but smaller than marketed. Removing the need for in-person site visits does expand the geographic catchment for a trial, but recruitment bottlenecks are often driven by disease awareness, eligibility criteria complexity, and site activation timelines, none of which decentralization alone fixes.
Diversity gains require deliberate design, not just remote access. Simply removing the requirement to travel to an academic medical center does not automatically enroll a more diverse population if the digital literacy, connectivity, and technology access required for the DCT's remote tools are themselves unevenly distributed. Several DCT programs have found that remote-first designs can inadvertently exclude older participants and those without reliable broadband, the opposite of the stated diversity goal.
Operational complexity is higher than advertised. Coordinating home health visits, local lab logistics, direct-to-patient drug shipment under proper chain-of-custody, and remote monitoring compliance introduces new points of failure that a single-site trial does not have. A 2024 review in Translational and Clinical Pharmacology focusing on FDA and EMA guidance found that operational and technological standardization across DCT vendors remains immature, complicating multi-region trials that mix decentralized elements differently by site. Source: Landscape of DCTs, FDA and EMA guidance review.
Where has decentralization clearly worked?
Not every finding is negative. Trials with simple, well-defined endpoints, established patient populations already comfortable with telehealth, and sponsors who invested in dedicated site-support infrastructure for the decentralized elements (rather than treating it as a pure cost-cutting measure) have shown genuine retention improvements, since reducing travel burden lowers dropout in long-duration chronic disease trials specifically.
What this does not prove
The current evidence does not prove decentralized trials are inferior to traditional trials on data quality or regulatory outcomes, the FDA's final guidance itself does not distinguish evidentiary standards by trial format. It does not prove decentralization cannot deliver the diversity and speed benefits it promises, only that those benefits have not been realized consistently across implemented programs to date. And it does not generalize across therapeutic areas: oncology trials with complex infusion regimens face different decentralization constraints than a chronic disease trial using oral medication and remote biomarker monitoring.
The takeaway
Decentralized trials now have a clear regulatory pathway and no lowered evidentiary bar, which is a meaningful maturation of the category. The honest read of the 2025 performance literature is that the promised gains in recruitment speed, diversity, and cost have been real in some programs and overstated in others, and the deciding factor is usually deliberate operational design rather than the decentralization label itself. Sponsors evaluating a DCT vendor should ask for realized recruitment and retention data from comparable prior trials, not the category's aggregate marketing claims.
